Editorial / what this is
About Script Sermorelin
An independent editorial reading of the GHRH(1-29) research record — laid out as a board of cited findings, nothing more.
What Script Sermorelin is
Script Sermorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin and GHRH(1-29). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site reads the literature the way a developer-tool reference board reads a system: each finding gets its own panel, with the study attached and the number cited. The aim is a record you can verify, not a pitch you have to trust.
About the name
The "script" in the domain is editorial framing, not a service. It signals the page's register — the prescribing-and-availability angle, the fact that sermorelin was once a prescription drug and is now a compounded substance — and it positions this publisher as a reader of that record. It is not a claim that the site writes prescriptions, fills scripts, dispenses anything, or connects anyone to a pharmacy. There is no clinic behind the console. The site sells nothing and offers no consultation.
How we handle evidence
Every quantitative statement on this site — a dose, a half-life, a percentage, a trial outcome — maps to a numbered citation on the full reference list, drawn from PubMed-indexed journals, controlled trials, and FDA references. We distinguish what the trials established (the pediatric height-velocity acceleration [1], the GH/IGF-1 reversal in older men [2], the pharmacokinetics [3]) from what remains open (long-term adult efficacy, which an Annals editorial judged not yet established [5]).
We are deliberate about the cognition lens: most of that evidence uses related analogs such as tesamorelin rather than sermorelin itself [6], and we say so wherever the topic appears. And we keep the regulatory history accurate — formerly FDA-approved for pediatric GH deficiency, withdrawn in 2008 for commercial reasons, now compounded under Section 503A [15] — because that history is so often misstated.
What this site is not
This is not medical advice, and nothing here is a recommendation to use sermorelin. The doses described are the doses studies administered to specific populations, reported as data. The material the literature concerns is research-grade GHRH(1-29) supplied for laboratory work, not a finished medicine or a compounded prescription. If you are weighing any health decision, that belongs with a qualified professional, not a research digest.